Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Economics Weekly: Record Profits, Lagging Pay

    In this Economics Weekly, Richard de Chazal looks at why pay has lagged in a tight labor market, and what that means for the Fed and for investors.

    Read more

  • Behind the Business of Women’s Sports

    Growing investment has helped reshape the business of women’s sports. Now, investors are looking more closely at what separates one opportunity from another.

    Read more

  • The Business of Making a Difference

    William Blair Chief Operating Officer Beth Satterfield explains how business leaders can use their experience, perspective, and relationships to drive community impact—and why the benefits often flow both ways.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures